Your browser doesn't support javascript.
loading
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).
Frias, Juan P; Bonora, Enzo; Nevarez Ruiz, Luis; Li, Ying G; Yu, Zhuoxin; Milicevic, Zvonko; Malik, Raleigh; Bethel, M Angelyn; Cox, David A.
Affiliation
  • Frias JP; National Research Institute, Los Angeles, CA.
  • Bonora E; Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy.
  • Nevarez Ruiz L; Hospital Angeles Chihuahua, Chihuahua, Mexico.
  • Li YG; Eli Lilly and Company, Indianapolis, IN.
  • Yu Z; Eli Lilly and Company, Indianapolis, IN.
  • Milicevic Z; Eli Lilly and Company, Indianapolis, IN.
  • Malik R; Eli Lilly and Company, Indianapolis, IN.
  • Bethel MA; Eli Lilly and Company, Indianapolis, IN.
  • Cox DA; Eli Lilly and Company, Indianapolis, IN cox_david_a@lilly.com.
Diabetes Care ; 44(3): 765-773, 2021 03.
Article in En | MEDLINE | ID: mdl-33397768
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Metformin Type of study: Clinical_trials Limits: Humans Language: En Journal: Diabetes Care Year: 2021 Document type: Article Affiliation country: Canada Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Metformin Type of study: Clinical_trials Limits: Humans Language: En Journal: Diabetes Care Year: 2021 Document type: Article Affiliation country: Canada Country of publication: United States